POLO trial for advanced pancreatic cancer: a new standard of care

(University of Chicago Medical Center) Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news